MCID: HYP078
MIFTS: 47

Hypertrophy of Breast

Categories: Genetic diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypertrophy of Breast

MalaCards integrated aliases for Hypertrophy of Breast:

Name: Hypertrophy of Breast 11 14 31 33
Excessive Development of Breast 33
Hypertrophy of Male Breast 33
Hypertrophy of Breast Nos 33
Hypertrophic Breast 33
Breasts Enlarged 11
Large Breast 11
Mastoplastia 33
Macromastia 33

Classifications:



External Ids:

Disease Ontology 11 DOID:10688
ICD9CM 34 611.1
NCIt 49 C3125
SNOMED-CT 68 43336006
ICD10 31 N62
ICD11 33 2078176266
UMLS 71 C0020565

Summaries for Hypertrophy of Breast

Disease Ontology: 11 A breast disease that is characterized by the progressive, excessive enlargement of breast connective tissue.

MalaCards based summary: Hypertrophy of Breast, also known as excessive development of breast, is related to aromatase excess syndrome and gynecomastia. An important gene associated with Hypertrophy of Breast is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Disease and Prolactin Signaling. The drugs Epirubicin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and lymph node, and related phenotypes are Decreased viability and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Hypertrophy of Breast

Diseases in the Hypertrophy of Breast family:

Hypertrophy of the Breast, Juvenile

Diseases related to Hypertrophy of Breast via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)
# Related Disease Score Top Affiliating Genes
1 aromatase excess syndrome 31.9 PGR ESR1 CYP19A1
2 gynecomastia 30.6 PGR ESR1 ERBB2 CYP19A1
3 breast abscess 30.3 PGR ERBB2
4 lipomatosis, multiple 30.1 TP53 PTEN PIK3CA
5 breast-ovarian cancer, familial 2 30.0 BRCA2 BRCA1
6 intraductal papilloma 29.8 PGR KRT5 ESR1 ERBB2
7 laryngeal benign neoplasm 29.8 TP53 PIK3CA EGFR
8 breast sarcoma 29.6 TP53 PGR KRT5 ESR1 ERBB2
9 breast disease 29.5 TP53 PGR MIR21 ESR1 ERBB2 CYP19A1
10 papilloma 29.4 TP53 PTEN KRT5 ERBB2 EGFR
11 breast fibroadenoma 29.1 TP53 PGR KRT5 ESR1 ERBB2 EGFR
12 ductal carcinoma in situ 28.5 TP53 PTEN PIK3CA PGR KRT5 GATA3
13 lobular neoplasia 28.5 TP53 PTEN PIK3CA PGR KRT5 ESR1
14 bilateral breast cancer 28.4 TP53 PTEN PGR ESR1 ERBB2 CYP19A1
15 hereditary breast ovarian cancer syndrome 27.9 TP53 PTEN PIK3CA PGR ESR1 ERBB2
16 ovarian cancer 27.6 TP53 PTEN PIK3CA PGR MIR21 MAP3K1
17 breast cancer 27.6 TP53 PTEN PIK3CA PGR MIR21 MAP3K1
18 uterine corpus adenosarcoma 10.4 PGR ESR1
19 scirrhous adenocarcinoma 10.4 PGR ERBB2
20 adult cystic nephroma 10.4 PGR ESR1
21 her2-receptor negative breast cancer 10.4 PGR ERBB2
22 vagina leiomyosarcoma 10.4 PGR ESR1
23 vulvar benign neoplasm 10.4 PGR ESR1
24 esophagus small cell carcinoma 10.4 PIK3CA ERBB2
25 glycogen-rich carcinoma 10.4 PGR ERBB2
26 hereditary site-specific ovarian cancer syndrome 10.4 BRCA2 BRCA1
27 progesterone resistance 10.4 PGR ESR1
28 ovary transitional cell carcinoma 10.4 BRCA2 BRCA1
29 apocrine adenosis of breast 10.4 TP53 ERBB2
30 nipple carcinoma 10.3 PGR ESR1 ERBB2
31 breast mucinous cystadenocarcinoma 10.3 PGR ESR1 ERBB2
32 breast fibroadenosis 10.3 PGR ESR1 ERBB2
33 cancerophobia 10.3 BRCA2 BRCA1
34 subserous uterine fibroid 10.3 PGR CYP19A1
35 bulbospinal polio 10.3 PGR ESR1 ERBB2
36 spinal polio 10.3 PGR ESR1 ERBB2
37 glycogen-rich clear cell breast carcinoma 10.3 PGR ESR1 ERBB2
38 breast cystic hypersecretory carcinoma 10.3 PGR ESR1 ERBB2
39 sebaceous breast carcinoma 10.3 GATA3 ERBB2
40 oncocytic breast carcinoma 10.3 PGR ESR1 ERBB2
41 nosophobia 10.3 BRCA2 BRCA1
42 progesterone-receptor negative breast cancer 10.3 PGR ESR1 ERBB2
43 tetraploidy 10.3 TP53 BRCA2
44 microglandular adenosis 10.3 PGR ESR1 ERBB2
45 breast adenomyoepithelioma 10.3 PIK3CA KRT5
46 cervical adenocarcinoma 10.3 TP53 PGR ESR1
47 cervical serous adenocarcinoma 10.3 PGR GATA3
48 intravenous leiomyomatosis 10.3 PGR ESR1
49 bartholin's gland adenoma 10.3 TP53 PGR ESR1
50 bartholin's gland benign neoplasm 10.3 TP53 PGR ESR1

Graphical network of the top 20 diseases related to Hypertrophy of Breast:



Diseases related to Hypertrophy of Breast

Symptoms & Phenotypes for Hypertrophy of Breast

GenomeRNAi Phenotypes related to Hypertrophy of Breast according to GeneCards Suite gene sharing:

25 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.72 PIK3CA EGFR
2 Decreased viability GR00055-A-2 10.72 PIK3CA EGFR
3 Decreased viability GR00107-A-1 10.72 MAP3K1
4 Decreased viability GR00221-A-1 10.72 ESR1 PIK3CA EGFR
5 Decreased viability GR00221-A-2 10.72 BRCA1 CHEK2 ESR1 MAP3K1 PIK3CA
6 Decreased viability GR00221-A-3 10.72 BRCA1 CHEK2 MAP3K1 ATM ERBB2
7 Decreased viability GR00221-A-4 10.72 CHEK2 ESR1 PIK3CA ATM ERBB2 EGFR
8 Decreased viability GR00301-A 10.72 BRCA1
9 Decreased viability GR00342-S-2 10.72 CHEK2
10 Decreased viability GR00386-A-1 10.72 ESR1
11 Decreased viability GR00402-S-2 10.72 ESR1 PIK3CA
12 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 BRCA1 BRCA2 PTEN PXDNL
13 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 ATM BRCA1 BRCA2 PTEN PXDNL TP53
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 ATM BRCA1 BRCA2 CHEK2 TP53
15 Increased apoptosis GR00093-A-0 9.46 ATM CHEK2 MAP3K1 PTEN
16 Increased cell death in HCT116 cells GR00103-A-0 8.65 PIK3CA

MGI Mouse Phenotypes related to Hypertrophy of Breast:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 ATM BRCA1 BRCA2 CHEK2 CUEDC2 CYP19A1
2 neoplasm MP:0002006 10.4 ATM BRCA1 BRCA2 CHEK2 CUEDC2 EGFR
3 nervous system MP:0003631 10.38 ATM BRCA1 BRCA2 CHEK2 CYP19A1 EGFR
4 growth/size/body region MP:0005378 10.36 ATM BRCA1 BRCA2 CYP19A1 EGFR ERBB2
5 endocrine/exocrine gland MP:0005379 10.34 ATM BRCA1 BRCA2 CHEK2 CYP19A1 EGFR
6 cellular MP:0005384 10.31 ATM BRCA1 BRCA2 CHEK2 CYP19A1 EGFR
7 muscle MP:0005369 10.3 BRCA1 CYP19A1 EGFR ERBB2 ESR1 GATA3
8 normal MP:0002873 10.27 BRCA1 BRCA2 CYP19A1 EGFR ERBB2 ESR1
9 immune system MP:0005387 10.24 ATM BRCA1 BRCA2 CHEK2 CUEDC2 CYP19A1
10 digestive/alimentary MP:0005381 10.23 BRCA1 BRCA2 CUEDC2 CYP19A1 EGFR ERBB2
11 embryo MP:0005380 10.22 ATM BRCA1 BRCA2 EGFR ERBB2 ESR1
12 cardiovascular system MP:0005385 10.22 ATM BRCA1 CHEK2 CYP19A1 EGFR ERBB2
13 limbs/digits/tail MP:0005371 10.2 BRCA1 BRCA2 EGFR ERBB2 ESR1 KRT5
14 adipose tissue MP:0005375 10.19 ATM BRCA1 CYP19A1 EGFR ESR1 GATA3
15 reproductive system MP:0005389 10.17 ATM BRCA1 BRCA2 CHEK2 CYP19A1 EGFR
16 pigmentation MP:0001186 10.14 BRCA1 CYP19A1 EGFR GATA3 MAP3K1 PTEN
17 skeleton MP:0005390 10.07 BRCA1 BRCA2 CYP19A1 EGFR ERBB2 ESR1
18 hematopoietic system MP:0005397 10 ATM BRCA1 BRCA2 CHEK2 CUEDC2 CYP19A1
19 mortality/aging MP:0010768 9.8 ATM BRCA1 BRCA2 CHEK2 EGFR ERBB2
20 integument MP:0010771 9.47 ATM BRCA1 BRCA2 CYP19A1 EGFR ERBB2

Drugs & Therapeutics for Hypertrophy of Breast

Drugs for Hypertrophy of Breast (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3 Alkylating Agents Phase 3
4 Anti-Bacterial Agents Phase 3
5 Antirheumatic Agents Phase 3
6 Antineoplastic Agents, Alkylating Phase 3
7 Antibiotics, Antitubercular Phase 3
8 Liposomal doxorubicin Phase 3
9 Immunologic Factors Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Multi-centre Study to Show Equivalence of Prineo (DERMABOND PROTAPE) to Intradermal Sutures for Skin Closure of Full-thickness Surgical Incisions Associated With Breast Procedures Completed NCT00558246 Phase 4
2 Randomized Pivotal Trial to Assess the Safety and Efficacy of Preoperative Focused Microwave Thermotherapy Plus Preoperative Chemotherapy Versus Preoperative Chemotherapy Alone for Cytoreduction of Large Breast Cancer in Female Patients With Intact Breast Unknown status NCT01204801 Phase 3 Chemotherapy (control)
3 The Difference in Presentation Level of Variant Receptors in Female Breast Tissue in Macromastia and Micromastia Unknown status NCT00173251 Phase 1
4 Randomized Controlled Trial Comparing Prone and Supine Intensity-modulated Radiotherapy (IMRT) After Breast-conserving Surgery in Patients With Large Breast Volume at High Risk for Skin Toxicity and Fibrosis Unknown status NCT00887523
5 Reduction Mammaplasty Safely Increases the Quality of Life in Patients With Mammary Hypetrophy. Completed NCT02769559
6 A Prospective, Randomized, Controlled Study to Evaluate Use of the PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction Completed NCT00986453
7 Satisfaction, Pain and Function Outcomes of Breast Reduction Patients: A Retrospective Chart Review and Patient Follow up Completed NCT05288530
8 An Observational Study Exploring the Esthetic Outcomes of Breast Reduction Surgery and /or Mastopexy Terminated NCT02016677
9 A Prospective, Randomized, Controlled Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0 Terminated NCT01284491
10 A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade® 4.0 in Bilateral Breast Reduction Withdrawn NCT01404351

Search NIH Clinical Center for Hypertrophy of Breast

Genetic Tests for Hypertrophy of Breast

Anatomical Context for Hypertrophy of Breast

Organs/tissues related to Hypertrophy of Breast:

MalaCards : Breast, Skin, Lymph Node, Lung, Temporal Lobe, Bone, Adipocyte

Publications for Hypertrophy of Breast

Articles related to Hypertrophy of Breast:

(show top 50) (show all 965)
# Title Authors PMID Year
1
The effects of breast reduction on pulmonary functions: A systematic review. 62
36229312 2022
2
Risk Factors Associated with Severe Macromastia among Adolescents and Young Women. 62
36103657 2022
3
Development and validation of a measure of curvy ideals internalization. 62
36191379 2022
4
High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues. 62
35930144 2022
5
Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer. 62
36050449 2022
6
Clavicular hook: Cuffed haemodialysis catheter insertion using a paramedian tunnel in patients with recurrent tip migration. 62
36401348 2022
7
Body Mass Index (BMI) Impact on Anesthetic Safety among Adolescents Undergoing Bilateral Reduction Mammaplasty. 62
36348755 2022
8
Comparing oncoplastic breast reduction with immediate symmetry surgery to standard breast reduction surgery: Are postoperative complications worse? 62
35801636 2022
9
The Impact of Combined Oral Contraceptives on Adolescents with Macromastia. 62
35862103 2022
10
Trends in insurance coverage for adolescent reduction mammaplasty. 62
35973871 2022
11
Stacked profunda artery perforator flaps with intra-flap anastomosis for moderate to large breast autologous reconstruction. 62
36205200 2022
12
Discussion: The Impact of Combined Oral Contraceptives on Adolescents with Macromastia. 62
36170439 2022
13
The Effect of Breast Size on Spinal Posture. 62
36280605 2022
14
Skin-reducing mastectomy and pre-pectoral breast reconstruction using the Braxon® ADM: a single-center experience. 62
34693673 2022
15
"Predicting Breast Reduction Resection Weights and Attainment of Insurance-Mandated Minimums: Sternal Notch-Nipple and Nipple-Inframammary Fold Distances Alone are Effective". 62
36194061 2022
16
A rare case of persistent large cystic breast tumor mimicking as malignant cystic breast cancer. 62
36412448 2022
17
The Batwing Mastopexy in Immediate Implant-Based Breast Reconstruction: An Aesthetic Enhancement for Patients with Cancer. 62
35766828 2022
18
[Genetic analysis and pathological features of one 46,XX testicular disorder of sex development cases with prostate germ cell tumor]. 62
36082576 2022
19
Symptomatic Macromastia and Days Lost from Work. 62
36018745 2022
20
Treatment of symptomatic macromastia in a breast unit. Outcomes analysis of breast reduction using BREAST-Q. 62
36100051 2022
21
A 53-year-old female with a large breast sarcoma: A case report from Hong Kong. 62
35769124 2022
22
Prognostic significance of CHAC1 expression in breast cancer. 62
35729480 2022
23
Reversible Gynecomastia in HIV-Infected Man Treated With Triple Antiretroviral Therapy Containing Efavirenz: A Case Report. 62
36120227 2022
24
The Supero-medial Pedicle in Patients with Macromastia Undergoing Nipple Sparing Mastectomy: A Better Option? 62
36002773 2022
25
A Systematic Literature Review of the Clinical Presentation, Management, and Outcome of Gestational Gigantomastia in the 21st Century. 62
35941388 2022
26
A Pure Autologous Dermal Graft and Dermal Flap Pocket in Prepectoral Implant Reconstruction After Skin-Reducing Mastectomy: A One-Stage Autologous Reconstruction Alternative to Acellular Dermal Matrices. 62
35138424 2022
27
Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial. 62
35930754 2022
28
Interactive exploration of a global clinical network from a large breast cancer cohort. 62
35948579 2022
29
Does Reduction Mammaplasty for Treatment of Macromastia Play a Role in the Functionality and Performance of Female Athletes? 62
35594425 2022
30
Reply: Does Reduction Mammaplasty for Treatment of Macromastia Play a Role in the Functionality and Performance of Female Athletes? 62
35594420 2022
31
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial. 62
35616948 2022
32
Morphological Dependence of Breast Cancer Cell Responses to Doxorubicin on Micropatterned Surfaces. 62
35890536 2022
33
How much error is associated with calculating breast volume from three-dimensional breast scans obtained when women are standing? Implications for bra design and bra fit. 62
35603985 2022
34
MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels. 62
35677646 2022
35
Long-term course of the changes in the nipple position after breast-conserving surgery. 62
35701689 2022
36
Neuroendocrine pathways and breast cancer progression: a pooled analysis of somatic mutations and gene expression from two large breast cancer cohorts. 62
35729536 2022
37
Modified goldilocks nipple-sparing mastectomy with immediate prepectoral implant-based reconstruction: a case report. 62
35694097 2022
38
Efficacy of Tranexamic Acid in Reducing Seroma and Hematoma Formation Following Reduction Mammaplasty. 62
35029651 2022
39
Favorable safety profile of moderate hypofractionated over normofractionated radiotherapy in breast cancer patients: a multicentric prospective real-life data farming analysis. 62
35443729 2022
40
Implant-based immediate reconstruction in prophylactic mastectomy: is the caudal dermis flap a reliable alternative to synthetic mesh or acellular dermal matrix? 62
34554314 2022
41
The importance of preoperative imaging methods in reduction mammoplasty. 62
34949572 2022
42
Electrocardiographic changes after breast reduction surgery. 62
35311464 2022
43
Challenges in Breast Evaluation: Breast Asymmetry, Macromastia, and the Surgically Altered Breast. 62
35168774 2022
44
[Does reduction mammoplasty improve neck pain and quality of life?] 62
35288798 2022
45
Delayed two-stage nipple sparing mastectomy and simultaneous expander-to-implant reconstruction of the large and ptotic breast. 62
35402205 2022
46
Analysis of adolescent patient satisfaction and well-being following reduction mammaplasty using the BREAST-Q survey. 62
34289933 2022
47
Comparing Outcomes after Oncoplastic Breast Reduction and Breast Reduction for Benign Macromastia. 62
35006098 2022
48
Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer. 62
35241110 2022
49
Unilateral breast reconstruction using double transverse upper gracilis (TUG) flaps. 62
34896045 2022
50
The Modified M-plasty Approach to Mastectomy: Avoiding the Lateral Dog-ear. 62
35198347 2022

Variations for Hypertrophy of Breast

Expression for Hypertrophy of Breast

Search GEO for disease gene expression data for Hypertrophy of Breast.

Pathways for Hypertrophy of Breast

Pathways related to Hypertrophy of Breast according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
2
Show member pathways
13.48 TP53 PTEN PIK3CA MAP3K1 ERBB2 EGFR
3
Show member pathways
13.08 TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
4
Show member pathways
12.94 TP53 MAP3K1 CHEK2 BRCA2 BRCA1 ATM
5
Show member pathways
12.88 PTEN PIK3CA MAP3K1 ERBB2 EGFR
6 12.85 PIK3CA PGR ESR1 ERBB2 EGFR
7
Show member pathways
12.85 TP53 PTEN GATA3 ESR1 BRCA1
8
Show member pathways
12.72 TP53 PTEN PIK3CA ERBB2 EGFR BRCA2
9
Show member pathways
12.7 PTEN PIK3CA ESR1 ERBB2 EGFR
10 12.69 ATM BRCA1 EGFR MAP3K1 PIK3CA PTEN
11 12.55 ATM BRCA1 BRCA2 CHEK2 CUEDC2 TP53
12
Show member pathways
12.53 EGFR ERBB2 MAP3K1 PIK3CA TP53
13
Show member pathways
12.53 TP53 MAP3K1 ESR1 CHEK2 BRCA2 BRCA1
14
Show member pathways
12.48 TP53 PTEN PIK3CA MAP3K1 ESR1 ERBB2
15
Show member pathways
12.46 TP53 PIK3CA ERBB2 EGFR CHEK2 ATM
16
Show member pathways
12.42 PIK3CA MAP3K1 ESR1 BRCA1
17
Show member pathways
12.39 BRCA1 CHEK2 ESR1 PGR
18
Show member pathways
12.39 TP53 CHEK2 BRCA1 ATM
19
Show member pathways
12.34 PIK3CA ESR1 ERBB2 EGFR
20 12.3 PTEN PIK3CA ERBB2 EGFR
21
Show member pathways
12.29 EGFR MAP3K1 PIK3CA PTEN
22
Show member pathways
12.28 TP53 PTEN PIK3CA GATA3
23
Show member pathways
12.24 TP53 PTEN CHEK2 BRCA1 ATM
24
Show member pathways
12.23 TP53 PTEN PIK3CA ERBB2 EGFR
25
Show member pathways
12.14 PTEN PIK3CA ERBB2 EGFR
26
Show member pathways
12.13 TP53 CHEK2 BRCA1 ATM
27 12.11 TP53 PTEN ERBB2 EGFR
28
Show member pathways
12.11 PIK3CA PGR ESR1 ERBB2 EGFR
29
Show member pathways
12.09 TP53 PTEN PIK3CA PGR ESR1 ERBB2
30
Show member pathways
12.04 TP53 PIK3CA ERBB2 EGFR
31
Show member pathways
12 PTEN PIK3CA MAP3K1 ERBB2 EGFR
32 11.9 TP53 PTEN PIK3CA
33
Show member pathways
11.87 ESR1 ERBB2 EGFR
34
Show member pathways
11.87 TP53 CHEK2 BRCA2 BRCA1 ATM
35
Show member pathways
11.85 TP53 CHEK2 BRCA1 ATM
36 11.81 TP53 PTEN PIK3CA MAP3K1 ERBB2 ATM
37 11.79 TP53 KRT5 GATA3
38
Show member pathways
11.78 TP53 CHEK2 ATM
39 11.77 TP53 PTEN ESR1
40
Show member pathways
11.75 TP53 CHEK2 BRCA2 BRCA1 ATM
41 11.74 TP53 PTEN ESR1
42 11.73 ESR1 EGFR ATM
43 11.72 TP53 MIR21 ATM
44 11.71 PGR ESR1 BRCA1
45 11.71 TP53 CHEK2 BRCA2 BRCA1 ATM
46 11.7 PTEN PIK3CA MAP3K1
47
Show member pathways
11.65 TP53 PTEN PIK3CA
48 11.63 EGFR ERBB2 PIK3CA PTEN TP53
49 11.57 TP53 CHEK2 ATM
50 11.54 KRT5 BRCA2 ATM

GO Terms for Hypertrophy of Breast

Cellular components related to Hypertrophy of Breast according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear ubiquitin ligase complex GO:0000152 9.26 BRCA2 BRCA1
2 DNA repair complex GO:1990391 9.1 BRCA2 BRCA1 ATM

Biological processes related to Hypertrophy of Breast according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-templated transcription GO:0045893 10.47 TP53 GATA3 ESR1 EGFR CHEK2 BRCA2
2 cellular response to DNA damage stimulus GO:0006974 10.29 ATM BRCA1 BRCA2 CHEK2 SPDYA TP53
3 positive regulation of gene expression GO:0010628 10.24 TP53 PGR MIR21 GATA3 ERBB2 BRCA1
4 positive regulation of protein kinase B signaling GO:0051897 10.13 EGFR GATA3 MIR21 PIK3CA
5 phosphorylation GO:0016310 10.1 PIK3CA MAP3K1 ERBB2 EGFR CHEK2 ATM
6 cell cycle GO:0007049 10.09 TP53 SPDYA CHEK2 BRCA2 BRCA1 ATM
7 negative regulation of gene expression GO:0010629 10.09 TP53 PIK3CA PGR MIR21 GATA3 ESR1
8 cellular response to ionizing radiation GO:0071479 10.07 TP53 BRCA2 BRCA1
9 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 10.01 TP53 CHEK2 BRCA2
10 cell population proliferation GO:0008283 10 TP53 PTEN GATA3 EGFR BRCA2
11 signal transduction in response to DNA damage GO:0006975 9.97 CHEK2 ATM
12 signal transduction in response to DNA damage GO:0042770 9.97 CHEK2 ATM
13 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.95 ATM CHEK2 TP53
14 uterus development GO:0060065 9.93 CYP19A1 ESR1 GATA3
15 female gonad development GO:0008585 9.91 ATM BRCA2 CYP19A1
16 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.9 TP53 ESR1
17 negative regulation of mammary gland epithelial cell proliferation GO:0033600 9.88 GATA3 BRCA2
18 replicative senescence GO:0090399 9.88 TP53 CHEK2 ATM
19 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.87 CHEK2 BRCA2 BRCA1 ATM
20 phosphatidylinositol 3-kinase signaling GO:0014065 9.86 PTEN PIK3CA GATA3 ERBB2
21 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.85 BRCA2 CHEK2 TP53
22 chordate embryonic development GO:0043009 9.78 BRCA2 BRCA1
23 cellular response to gamma radiation GO:0071480 9.7 ATM CHEK2 MIR21 TP53
24 positive regulation of miRNA maturation GO:1903800 9.62 TP53 EGFR
25 response to gamma radiation GO:0010332 9.5 TP53 GATA3 CHEK2 BRCA2
26 double-strand break repair GO:0006302 9.32 TP53 CHEK2 BRCA2 BRCA1 ATM

Molecular functions related to Hypertrophy of Breast according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 10.1 TP53 SPDYA PTEN MAP3K1 ESR1 CHEK2
2 transcription coactivator binding GO:0001223 9.73 PGR GATA3 ESR1
3 enzyme binding GO:0019899 9.73 BRCA1 EGFR ESR1 PGR PTEN TP53
4 kinase activity GO:0016301 9.7 PIK3CA MAP3K1 ERBB2 EGFR CHEK2 ATM
5 identical protein binding GO:0042802 9.66 TP53 PTEN PGR GATA3 ESR1 ERBB2

Sources for Hypertrophy of Breast

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....